Aaron S. Farberg, MD

Articles by Aaron S. Farberg, MD

Pearls for Atopic Dermatitis Management

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter A. Lio, MD, Northwestern University Feinberg School of Medicine ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 26th 2023

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Patient Adherence in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter A. Lio, MD, Northwestern University Feinberg School of Medicine ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 26th 2023

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Use of Tralokinumab in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter A. Lio, MD, Northwestern University Feinberg School of Medicine ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 26th 2023

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Impact of Dupilumab on Quality of Life for Atopic Dermatitis Patients

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 19th 2023

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Efficacy and Reported Outcomes With JAK Inhibitors in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 19th 2023

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

Ideal Candidates for Ruxolitinib Treatment of Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 12th 2023

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Safety Profile of Topical Ruxolitinib in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Aaron S. Farberg, MD,Alexandra K. Golant, MD

May 12th 2023

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Clinical Trials of Topical Ruxolitinib in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 5th 2023

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.

Overview of JAK Inhibitors in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 5th 2023

Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.

Assessing Severity of Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 28th 2023

Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.

Treatment Approach to Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 28th 2023

Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.

Traditional Steroids vs Emerging Therapies in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 21st 2023

Alexandra Golant, MD, comments on the adverse events of systemic therapies and how emerging nonsteroidal agents have a better safety profile in atopic dermatitis.

Treatment Landscape in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 21st 2023

Matthew Zirwas, MD, highlights therapies that are available for the treatment of atopic dermatitis, including corticosteroids, calcineurin inhibitors and JAK inhibitors.